HORIZON EUROPE 2026
Antti Vuolanto, CEO of Herantis Pharma, said: “We are absolutely delighted to have been selected for this non-dilutive funding from Horizon Europe. This grant will make a meaningful contribution to the funding of our Phase 2 proof-of-concept study for HER-096, the resourcing of which we are continuing to discuss with potential investors and strategic partners. Being selected from a highly competitive field of innovative European companies further validates our scientific approach and underscores the potential of HER-096 to improve outcomes for people living with Parkinson’s disease. I would like to thank the European Commission for its support and look forward to providing further updates once the agreement is signed, and the study design has been finalized.”
The ‘Boosting the translation of biotech research into innovative health therapies’ topic, which forms part of the wider Horizon Europe 2025 Health initiative, is designed to accelerate the translation of promising biotech research into clinical development and aims to deliver the following outcomes:
- Faster access to innovative therapies for healthcare providers, researchers and patients
- Increased number of clinical trials evaluating novel biotech therapeutic approaches conducted within the European Union
- Strengthened competitiveness of small and medium-size enterprises (SMEs) in the EU and Associated Countries within the health biotech sector
More information on the Horizon Europe Health initiative can be found here.
For more information, please contact:
Herantis Pharma:
Antti Vuolanto, CEO
Tel: +358407517329